Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Next Previous
Trial Profile

Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inaticabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 10 Dec 2024 Results (n=48 As of the data cutoff date of 2 April 2024) assessing safety and efficacy of of Inaticabtagene Autoleucel in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia presented at the 66th American Society of Hematology Annual Meeting and Exposition
  • 06 Jun 2024 Planned End Date changed from 1 Mar 2024 to 31 Dec 2026.
  • 08 Nov 2023 According to a CASI Pharmaceuticals media release, the China National Medical Products Administration (NMPA) has granted market approval for Juventas' investigational cell therapy, Inaticabtagene Autoleucel (CNCT 19), for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in China.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top